Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - March 2013

18th Congress of The European Association of Hospital Pharmacists (EAHP)

13 Mar 2013 - 15 Mar 2013 - Palais des Congrès, Paris, France

Bookmark and Share

The European Association of Hospital Pharmacists (EAHP) is a working community of national associations of hospital pharmacists. Membership is increasing each year and, at present, EAHP represents the interest of over 21,000 hospital pharmacists in 32 countries all over Europe.

EAHP’s annual congress is the largest congress for hospital pharmacy in Europe and is attended by professionals from over 50 countries. Approximately 4.000 hospital pharmacists are expected to attend the 18th Congress of the EAHP next 13-15 March 2013 at the Palais des Congrès in Paris, France.

“Improving patient outcomes – a shared responsibility”  will be the theme for the presentations at the Paris 2013 EAHP Congress. A scientific programme including 3 keynote presentations, 13 seminars open for interactions with the speakers and 3 interactive workshops will offer participants the unique opportunity to meet, network and share expertise. EAHP’s industry partners have also committed to conducting satellite symposia highlighting important new developments important to hospital pharmacy.

EAHP’s Congress is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education, as well as by some of its national member associations according to the different national accreditation systems.

Register online to attend the EAHP 18th Congress.

Deadline for submission is 15 October 2012.  Original contributions from all fields of hospital pharmacy are welcomed for poster presentation. 

For further information, please visit the website, where you will also be able to find more details on our scientific programme.

The registration fees are set follows :


— before 1 December 2012  € 600

— beginning 1 December 2012 € 700

— beginning 1 February 2013 € 800


Registration fee includes access to all sessions, the opening reception, the exhibition, lunches on Wednesday, Thursday, Friday and coffee/tea during official breaks.


Registration fee includes 19,6% VAT until 1 October and 21,2% afterwards according to French law.

Further information
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos